PubMed | Griffith University, a Princess Alexandra Hospital and Applied Brain Research
Type: Journal Article | Journal: Journal of social work in disability & rehabilitation | Year: 2016
This scoping review investigated risk factors, impacts, outcomes, and service implications of violence-related traumatic brain injury (TBI) for individuals and their informal caregivers. A systematic search (Web of Science, PubMed, PsycInfo, ProQuest, Medline, Informit; 1990-2015) identified 17 studies meeting the inclusion and exclusion criteria. Violence was the cause of between 3% and 26% of all TBIs. Males, a non-White racial background, preinjury unemployment, and preinjury substance abuse problems all elevated the risk for sustaining a violence-related TBI compared to other-cause TBI. However, few differences were observed in 12 months postinjury outcomes. No studies investigated the impact of violence-related TBI on informal caregivers.
News Article | November 1, 2016
Reston, Virginia - Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of "The Journal of Nuclear Medicine." Amyloidosis eventually leads to dysfunction of the affected organs. When the heart is affected, the prognosis is extremely poor. Dr W. Phillip Law, the corresponding author of the study, explains, "The first signs and symptoms of the disease are nonspecific and usually attributed to other conditions. Currently, there is no definitive test to diagnose cardiac amyloidosis other than an invasive biopsy of the heart muscle. Cardiac amyloidosis is often not diagnosed until late in the course of the disease, as the typical appearance of the infiltrated myocardium on echocardiography and MRI can be mistaken for other more prevalent disorders." While previous research of amyloid radiotracers in the heart has used normal subjects as controls, this study compared subjects with thickened heart muscle secondary to amyloid deposition to those with thickened myocardium due to hypertensive heart disease. Being able to visualize and quantify amyloid deposition in heart muscle may provide an accurate and noninvasive means of diagnosing the disorder and also may be useful in monitoring disease burden. F-18-florbetaben PET was performed in 14 subjects. Target-to-background standardized uptake values (SUV) ratio and percentage myocardial radiotracer retention were higher in amyloid patients compared to hypertensive control subjects. A cut-off value of 40 percent was able to differentiate between cardiac amyloid patients and hypertensive control subjects. The study shows that F-18-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease. Percentage myocardial F-18-florbetaben retention was an independent determinant of myocardial dysfunction in cardiac amyloidosis. Looking ahead, Dr Law envisions, "Tailored molecular imaging with PET using florbetaben may significantly simplify the diagnostic algorithm for patients with suspected cardiac amyloidosis. Future studies investigating florbetaben uptake pattern in other [non-amyloid, non-hypertensive] causes of heart muscle thickening would further clarify the specificity of florbetaben." He adds, "The relationship of PET quantification of florbetaben retention in the heart, with histological amyloid plaque burden, may provide another means of monitoring disease and could also be useful in monitoring response of cardiac amyloid to treatment, but further research needs to be undertaken to investigate this relationship." Authors of the article "Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study" include W. Phillip Law, University of Queensland and Princess Alexandra Hospital, Brisbane, Australia, and William Y.S. Wang, Peter T. Moore, Peter N. Mollee, and Arnold C.T. Ng, Princess Alexandra Hospital, Brisbane, Australia. This work was funded in part by a Princess Alexandra Hospital Research Foundation grant and a National Health and Medical Research Council early career fellowship. Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm. . About the Society of Nuclear Medicine and Molecular Imaging The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible. SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www. .